Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ophthotech

Novartis day

Novartis’ Swiss head of operations reveals job cuts

Leuenberger suggests cuts are needed to maintain competiveness

Bayer symbol

Bayer’s lymphoma drug copanlisib gets speedy FDA review

The PI3K inhibitor will be assessed for relapsed or refractory follicular lymphoma

Roche Basel Switzerland

Tecentriq bladder cancer approval in doubt after trial failure

The PD-L1 inhibitor failed to extend overall survival in a phase III study

- PMLiVE

Novartis’ Rydapt approval ends long AML therapy drought

Targeted blood cancer drug wins US licence from the FDA

- PMLiVE

Sandoz UK promotes Tim de Gavre to country head

He succeeds Stephan Eder who becomes country head for Sandoz Germany

Bayer symbol

FDA OK for Stivarga ends decade-long drought in liver cancer

Bayer's medicine wins US approval to treat hepatocellular carcinoma

- PMLiVE

New drugs can’t keep Novartis sales on the up

Total group sales down 1% despite Cosentyx profit

Roche Basel Switzerland

Roche claims another FDA green light for Tecentriq

Wins approval for the treatment's first-line use in bladder cancer

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

Roche Basel Switzerland

Roche’s Alecensa beats Xalkori as first-line lung cancer therapy

Data shows ALK inhibitor reduces risk of disease worsening

- PMLiVE

Novartis gets lung cancer OK for Tafinlar/Mekinist combo

It can now be used to treat BRAF V600E-positive NSCLC patients in Europe

Novartis day

Novartis files CAR-T therapy in US, with swift review

CTL109 candidate gets FDA priority review status

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links